New Pharmanovia Study Results Reveal Chloral Hydrate Noticeably Improves Severe Insomnia Within Two Weeks

Contributed by: Business Wire

Logo

Tags

Mental Health

Health

Neurology

Clinical Trials

Research

Science

Pharmaceutical

Insomnia

More Like This

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

NICE recommends Idorsia's QUVIVIQ™ (daridorexant) for adults with chronic insomnia

PR Newswire associated0

Flow Health Science to Present New Klario® Hypoglycaemia Data at Diabetes UK 2026

PR Newswire associated0

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

PR Newswire associated0

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

PR Newswire associated0

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)